MERCK LAUNCHES PLENDIL AT 23%-TO-60% DISCOUNT

MERCK LAUNCHES PLENDIL AT 23%-TO-60% DISCOUNT to other once-a- day calcium channel blockers indicated for hypertension, the company announced Sept. 24. Shipments of Plendil (felodipine) began Sept. 16, the company said. Direct price to wholesalers of 5 mg Plendil is $ 64 for 100 tablets and $ 115 for 100 tablets of 10 mg strength. "Plendil offers highly effective blood pressure reduction, convenient dosing and unequaled value for once-daily calcium channel blocker therapy," Merck said in a press release announcing the launch. Plendil was approved on July 25 ("The Pink Sheet" Aug. 5, T&G-13). Merck based its calculations of the discount on the price per tablet of the recommended starting doses of Plendil, Pfizer's Procardia XL (nifedipine), Searle's and Knoll's Calan SR/Isoptin SR (verapamil), and Lederle/Wyeth-Ayerst's Verelan (verapamil). Merck used direct price to wholesalers for its comparisons, except for Calan SR and Isoptin SR where only average wholesale price was reported. According to Merck, the price per tab for each of the products is: 64" for 5 mg Plendil; 89" for 30 mg Procardia XL; $ 1.60 for 60 mg Procardia XL; 94" for 180 mg Calan SR/Isoptin SR; and 83" for 240 mg Verelan. The price for a 10 mg tablet of Plendil would be $ 1.15, which is more expensive than the highest dose for each of the other products except Procardia XL, which costs $ 1.91 per 90 mg tablet, according to Medi-Span. Merck's decision to compete on price with Plendil reinforces the perception that price competition among new branded products is developing. Another recent example is Ciba-Geigy's launch of Lotensin, the seventh ACE inhibitor, at a 10%-to-44% discount to other ACEs ("The Pink Sheet" July 29, T&G-3). The Lotensin discount was tied to a lifetime price guarantee and its marketing included letters to physicians and a patient enrollment program. Merck did not reveal any details of its marketing program. The Plendil discount nevertheless appears to be more aggressive discounting than previous entries by Merck into established categories. Merck introduced Vasotec at a 23% lower cost per day than Bristol-Myers Squibb's Capoten, although variation in dosing regimens makes comparison difficult. Merck also launched the H[2] antagonist Pepcid at a discount to Glaxo's Zantac, although it was slightly more expensive than SmithKline's Tagamet. The pricing decision on Plendil also raises the question of how Merck will position its second HMG-CoA- inhibitor Zocor, once it is approved against Bristol-Myers Squibb's Pravachol and Merck's own Mevacor. Both Pravachol and Zocor could be approved within the next year. Plendil is the third Astra drug launched by Merck under a $ 60 mil. agreement reached in the early 80s. Tonocard and Prilosec are the other two. If the Astra products reach an unspecified trigger point in volume, an Astra-Merck joint venture will be set up in 1993. On June 1, Merck named Wayne Yetter as General Manager Astra/Merck Affairs. Yetter's varied background with MSD and Pfizer is indicative of the importance Merck assigns to its relationship with Astra. Prices for calcium channel blockers as a class increased 3.7% in the first half of 1991, according to drug price data from First DataBank. That increase was almost the same as the average 3.8% price increase for all drugs during the first half. Less than a third of the currently marketed calcium channel blockers showed price increases, according to First DataBank. Among those drugs increasing in price, the average increase was 12.4%. The two leading calcium channel blockers, Marion Merrell Dow's Cardizem and Pfizer's Procardia, showed price increases of about 5%, according to First DataBank.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By 

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.

Report Shows Extent Of AI Use In EU Medicines Regulation During 2024

 

The AI observatory, created by the European medicines regulatory network to track the evolving use of artificial intelligence in medicines development and regulation, has issued its first annual report.

Prasad Cites Unproven Theory Defending His COVID-19 Vaccine Decisions

 

In defending his decision to overrule agency staff on three recent COVID-19 vaccine applications, the CBER director questioned the original timing of Pfizer’s COVID-19 vaccine authorization, reviving a long-held, but unproven grievance of President Trump.